Author

Victoria Clendaniel

Observed name: V Clendaniel

Institution: Verve Therapeutics (United States)

Observed institutions: Beth Israel Deaconess Medical Center, Beth Israel Deaconess Hospital, Victoria University of Wellington, Verve Therapeutics (United States)

ORCID: 0000-0002-2969-4443

Observed ORCID: 0000-0002-2969-4443

OpenAlex ID: A5074019877

In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates

2021 · Kiran Musunuru, Alexandra C. Chadwick, et al. · Nature · 831

Histone Deacetylase 3 Inhibition Decreases Cerebral Edema and Protects the Blood–Brain Barrier After Stroke

2022 · Hui Lu, Ryan Ashiqueali, et al. · Molecular Neurobiology · 43

Neuroprotective Effects of Selective Inhibition of Histone Deacetylase 3 in Experimental Stroke

2020 · Rudy Matheson, Kohei Chida, et al. · Translational Stroke Research · 30

An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves precise and durable liver editing in nonclinical studies

2024 · Richard Lee, Anne Mazzola, et al. · Atherosclerosis · 14

An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves potent and LDLR-independent liver editing in mouse models

2023 · R Lee, J Denizio, et al. · European Heart Journal · 12

Engineered T7 RNA polymerase to improve mRNA capping efficiency and reduce dsRNA generation during in vitro transcription

2026 · Athul Sanjeev, Casey Hannigan, et al. · Molecular Therapy Advances · 1

Histone Deacetylase 3 Inhibition Decreases Cerebral Edema and Protects the Blood-Brain Barrier after Stroke (S33.001)

2022 · Hui Lu, Chin Lin, et al. · Neurology

Abstract TP272: Selective Inhibition of Histone Deacetylase 3 Decreases Cerebral Edema and Blood-Brain Barrier Leakage

2020 · Amjad Shehadah, Hui Lu, et al. · Stroke

Works count: 8

Citation count: 931

H-index: 5

I10-index: 5